EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications

Ying Cong, Rianne Biemans, Natasja G Lieuwes, Dennis Suijlen, Philippe Lambin, Ingrid Dijkgraaf, Matthias Bauwens, Ala Yaromina, Ludwig J Dubois iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07321-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Ying Cong und 8 weiteren Autor:innen. Beteiligte Einrichtung: The M-Lab, Department of Precision Medicine, GROW- Research Institute for Oncology and Reproduction, Maastricht University, UNS50/23, Maastricht, PO …. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Single Photon Emission Computed Tomography Computed Tomography, Carcinoembryonic Antigen, Tomography, Emission-Computed, Single-Photon. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship, ERC Advanced - Hypoximmuno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In this study, we investigated the utility of a novel developed anti-CEACAM5 VHH for cancer diagnosis and its potential of being a targeting-moiety of VHH-drug conjugates for cancer therapy.

Methods

Anti-CEACAM5 VHH (6B11) affinity and specific cellular binding was confirmed by ELISA, FACS and immunofluorescence in cancer cell lines with varying CEACAM5 expression levels. Intracellular penetration ability within tumor spheroids was tested with Oregon Green 488 labeled 6B11 (OG488-6B11). Biodistribution and binding specificity of 99m Tc-radiolabeled 6B11 was tested in A549 CEACAM5 overexpressing (A549-CEA5-OV) and knockout (A549-CEA5-KO) tumor-bearing mice upon SPECT/CT imaging, γ-counting and autoradiography. The therapeutic efficacy of 6B11 and 6F8 (anti-CEACAM5 VHH with lower binding affinity) was tested by viability, wound healing and adhesion assays. To verify the potential of VHHs as a warhead for VHH-drug conjugation, an internalization assay with OG488 labeled VHH was performed.

Result

6B11 demonstrated high binding affinity (EC 50 0.5nM) and cellular binding. OG488-6B11 penetrated tumor spheroids completely at 24 h, while a conventional antibody was only visible at the spheroid periphery. SPECT imaging indicated higher uptake ( p < 0.05) in A549-CEA5-OV tumors, resulting in increased tumor-to-blood ratios especially at 4 (2.0016 ± 1.1893, p = 0.035) and 24 (2.9371 ± 2.0683, p = 0.003) hpi compared to A549-CEA5-KO tumors at 4 (0.5640 ± 0.3576) and 24 (0.8051 ± 0.4351) hpi. 99m Tc-6B11 was predominantly renally cleared. Autoradiography and immunohistochemistry confirmed these uptake patterns. 6B11 nor 6F8 did exhibit significant anti-cancer therapeutic efficacy in vitro. OG488-6B11 was effectively internalized and accumulated in cells in a time-dependent manner, to end up in the lysosomes.

Conclusion

The anti-CEACAM5 VHH 6B11 is a good candidate for SPECT-based cancer diagnosis and can be potentially used as targeting moiety in the development of VHH-based drug conjugates for cancer treatments. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesSingle Photon Emission Computed Tomography Computed TomographyCarcinoembryonic AntigenTomography, Emission-Computed, Single-PhotonNeoplasmsHumansAnimalsMiceTissue DistributionCell Line, TumorGPI-Linked Proteins

Stichwörter der Autor:innen

99mTc-VHHBiodistributionCEACAM5SPECT imagingVHH-based drug conjugate

Substanzen

Single-Domain AntibodiesCEACAM5 protein, humanCarcinoembryonic AntigenGPI-Linked Proteins

Autor:innen und Institutionen

  • The M-Lab, Department of Precision Medicine, GROW- Research Institute for Oncology and Reproduction, Maastricht University, UNS50/23, Maastricht, PO Box 616, 6229 ER, Maastricht, The Netherlands.
  • Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  • The M-Lab, Department of Precision Medicine, GROW- Research Institute for Oncology and Reproduction, Maastricht University, UNS50/23, Maastricht, PO Box 616, 6229 ER, Maastricht, The Netherlands. ludwig.dubois@maastrich…

ORCID-Profile: Ludwig J Dubois

Förderung

  • China Scholarship
  • ERC Advanced - Hypoximmuno

Zitieren

APA

Cong, Y., Biemans, R., Lieuwes, N. G., Suijlen, D., Lambin, P., Dijkgraaf, I., Bauwens, M., Yaromina, A., & Dubois, L. J. (2025). Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07321-z

Vancouver

Cong Y, Biemans R, Lieuwes NG, Suijlen D, Lambin P, Dijkgraaf I, et al. Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07321-z

BibTeX
@article{Cong2025,
  author = {Cong, Ying and Biemans, Rianne and Lieuwes, Natasja G and Suijlen, Dennis and Lambin, Philippe and Dijkgraaf, Ingrid and Bauwens, Matthias and Yaromina, Ala and Dubois, Ludwig J},
  title = {Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07321-z}
}
Kostenlos starten →